p53 and DNA methylation play key roles in the maintenance of genome stability. In this work, we demonstrate that the two mechanisms are linked and that p53 plays a role in the maintenance of the DNA methylation levels. The loss of p53 was shown to induce loss of DNA methylation in the TROP1 gene, a human cancer-expressed locus that undergoes amplification when hypomethylated. This demethylation was reverted by the reintroduction of a wild-type TP53 (wtTP53) in the TP53-null cells. Using a gene-amplification assay in vivo, we demonstrate that the loss of p53 leads to a demethylationdependent TROP1 gene amplification. The induction of gene amplification was reverted by the expression of a wtTP53 gene or by in vitro methylation of the transfected DNA with the Sss I DNA methylase. Taken together, these findings demonstrate that the inactivation of TP53 induces loss of DNA methylation and DNA methylationdependent gene amplification.
Introduction
The tumor suppressor TP53 is frequently inactivated in cancer and this loss of function plays a key role in tumor progression (Hollstein et al., 1991) . p53 triggers growth arrest and apoptosis when activated in response to DNA damage (Levine, 1997) . The loss of this gatekeeping function permits a continuous growth of p53-null cells, in spite of heavy mutation loads, and allows the accumulation of growth-favoring genetic mutations (Levine, 1997) . Less recognized is the role of p53 in the control of genome stability (Livingstone et al., 1992; Yin et al., 1992; Bertrand et al., 1997; Carroll et al., 1999; Saintigny and Lopez, 2002) .
Genomic rearrangements are a key pathway of genetic change and a powerful driving force of tumor progression (Lengauer et al., 1998) . Hence, the genomic instability that follows the inactivation of the TP53 gene in tumor cells (Livingstone et al., 1992; Yin et al., 1992 ) is likely to contribute critically to tumor progression.
DNA methylation plays a key role in the maintenance of chromatin structure and of the integrity of the genome (Hori, 1983; Xu et al., 1999; Tuck-Muller et al., 2000) . Indeed, alterations of DNA methylation induce genetic instability in normal cells (Perry et al., 1992) , in tumor tissues (Lengauer et al., 1997) and in hereditary diseases (Xu et al., 1999; Tuck-Muller et al., 2000) , and cause gene amplification (Perry et al., 1992; Alberti et al., 1994) . Altered DNA methylation increases DNA recombination (Hsieh and Lieber, 1992; Ahuja et al., 1997) and sister-chromatid exchange (Hori, 1983) . Notably, cytosine methylation also modulates the interaction of repair enzymes with DNA (Hare and Taylor, 1985) . Consistent with this model of DNA methylationmediated control of genomic stability, genome-wide alterations of DNA methylation levels (overall hypomethylation and local hypermethylation (Soares et al., 1999) ) are frequently found in cancer cells and correlate with specific stages of tumor progression (Goelz et al., 1985; Feinberg et al., 1988) . Alterations of DNA methyltransferase levels and/or activity are frequent in tumors (el-Deiry et al., 1991; Issa et al., 1993; Patra et al., 2001) , and cause alterations of DNA methylation in different genes, at different stages of tumor progression and in diverse tumors (Laird et al., 1995; Esteller et al., 2001) . Based on these findings, we argued that p53 might act as an upstream controller of the DNA methylation apparatus, and that an altered regulation of DNA methylation might be a key mediator of a loss of control over the stability of the genome.
We have investigated this possible regulatory role of p53 on DNA methylation. Several different technologies can provide significant information on the overall methyl-C content of DNA (Robertson and Wolffe, 2000; Pradhan and Kim, 2002 and references therein) . Southern blot analysis can provide direct information on the methylation status at specific CpG sites (Robertson and Wolffe, 2000) . However, little is known on the DNA sequences that are important for a methylation-mediated control of genome stability (Hori, 1983; Perry et al., 1992; Lengauer et al., 1997; Xu et al., 1999; Tuck-Muller et al., 2000; Robertson and Wolffe, 2000) and a direct in vitro assay for this functional role is missing. The amplification of the TROP1 gene was demonstrated to be regulated by DNA methylation in transfected cells (Alberti et al., 1994) . Albeit laborintensive, this in vivo gene amplification assay has key advantages. The first one is the ability to analyse the amplification of a gene in its native DNA methylation state. Genomic DNA from different cellular sources is assayed upon transfection in the same cell line, which effectively prevents a differential gene amplification ability of diverse cells (Giulotto et al., 1987; Wright et al., 1990) . Finally, the amplification of the TROP1 gene is neutral to the survival of the transfected L cells (Alberti et al., 1994) , thus preventing a growth-related bias in the selection for amplificants.
Cells from Li-Fraumeni syndrome patients carry a germline mutation of TP53 (Malkin et al., 1990) . Earlypassage cells are mortal in culture and do not form tumors . However, Li-Fraumeni cells undergo a growth crisis with time in culture and inactivate the remaining copy of TP53 (Livingstone et al., 1992; Yin et al., 1992) . The loss of function of p53 causes vast genome rearrangements and gene amplification, which can be reverted by the reintroduction of a wild-type (Wt) TP53 (Yin et al., 1992) . Hence, Li-Fraumeni cells provide a system where to study the changes in genome stability induced by the transition from a TP53-heterozygous to a TP53-null state. Taking advantage of the tools above, we demonstrate that the loss of TP53 leads to a loss of DNA methylation and to DNA methlylation-dependent gene amplification.
Materials and methods

Cells
JML 172, MDAH041 and MDAH087 are cell strains from LiFraumeni patients . JML 172 at the 11th passage (wt/mut A) and MDAH087 at the 12th passage (wt/ mut B) are mortal cell populations that retain one copy of wtTP53. JML 172 at passage 132 (mut/mut A), MDAH041 at passage 177 (mut/mut B) and MDAH087 at passage 100 (mut/ mut C) are immortalized cell cultures that have inactivated both copies of wtTP53 Livingstone et al., 1992; Yin et al., 1992) . All cells were maintained in DMEM supplemented with 10% fetal calf serum (Alberti et al., 1994) . Human peripheral blood leukocytes (PBL) and human embryonal fibroblasts were used as control cells with two copies of the wtTP53.
Southern blotting
DNA from cell lines and transfected (tr) cells was analysed by Southern blotting as described (Sambrook et al., 1989) . The level of cytosine methylation was assessed by comparison of DNA methylation-sensitive (HpaII) and insensitive (MspI) restriction enzymes. Filters were hybridized with the KSI-4/ Trop-1 probe (Strand et al., 1989) . l DNA cut with Hind III or 1 kb DNA ladder (Gibco-BRL Life Technologies, Paisley, UK) were used as molecular weight standards.
The intensity of the signals revealed by autoradiography was quantified with the program NIH-image 1.62. The copy number of the transfected genes was determined by comparison with the hybridization signal from PBL DNA. Southern filter lanes loaded with 0.5 Â , 1 Â and 2 Â PBL DNA were used to construct an experimental standard reference curve. Gray-scale standards (Kodak) were used to construct an exponentially fitted standard reference curve for light absorbance quantification.
DNA transfection
The calcium phosphate coprecipitation technique was followed as described (Alberti et al., 1994) . Transfections were performed with 10 mg of guanidinium-purified genomic DNA from the Li-Fraumeni cell lines coprecipitated with 1 mg of plasmid containing the thymidine-kinase gene. Transfected cells were selected by growth in HAT medium. To ensure the analysis of independent transfection events, transfections of genomic DNA were separately performed in 10-cm-diameter plates, and each of these was independently selected for Trop-1 expression by flow cytometry (Alberti et al., 1994 ) (see below).
In vitro DNA methylation DNA (200 mg) from Li-Fraumeni cell lines was methylated at CpG sites in vitro by the SssI DNA methylase, 70 U, in the presence of 32 mm S-adenosyl-methionine (SAM) as methyl donor. Corresponding amounts of fresh SssI and SAM were added every 8 h and the reaction was allowed to proceed for 24 h at 371C before extraction with phenol and chloroform.
Antibodies
The 162-21.2 hybridoma cells secreting anti-Trop-1 monoclonal antibodies (mAb) were injected i.p. in nude mice. mAb were purified from mouse ascites and fluorescein-conjugated as previously described (Alberti et al., 1994) .
Selection for TROP1-amplified cells by immunofluorescence flow cytometry
The selection procedure is schematically depicted in Figure 2 . Fluorescence analyses and sorts were performed with a fluorescence-activated cell sorter (Vantage, Becton, Dickinson Sunnyvale, CA, USA) (Alberti et al., 1994) . Pure populations of Trop-1-expressing transfected cells were obtained. To select for cells that amplified the TROP1 gene, 0.1% of the cells with the highest Trop-1 expression were sorted from each transfectant, regrown and sorted again (Alberti et al., 1994) . DNA was extracted from all transfectants at each stage of the selection procedure and analysed by Southern blotting.
Results
DNA methylation status of the TROP1 gene in Li-Fraumeni cells
Preliminary findings demonstrated overall hypomethylation of TP53-null cells by digestion of genomic DNA with the McrBC nuclease (Pradhan and Kim, 2002) (unpublished) . As the TROP1 gene undergoes a DNA methylation-dependent gene amplification (Alberti et al., 1994) , it was of interest to determine if DNA methylation changes occurred in this gene in the TP53-null 
Generation of TROP1 transfectants from Li-Fraumeni cell DNA
Southern blot analysis of the demethylated sites of the TROP1 gene in Li-Fraumeni cells did not allow to pinpoint changes of DNA methylation that would be structurally and functionally relevant for gene amplification. To gain insight into the latter, we utilized a functional in vivo assay for gene-amplification-prone DNA methylation changes. In this, L cells are utilized as a 'living test-tube', which is permissive for DNA methylation-driven amplification of transfected genes (Alberti et al., 1994) (Figure 2 ). DNA from LiFraumeni cells that retained one copy of the wtTP53 or had inactivated both copies of the gene was transfected in L cells. DNA from normal cells homozygous for the wtTP53 gene was analysed in parallel. Several independent genomic TROP1 transfectants were generated: 25 from cells devoid of functional p53, eight from heterozygous and 10 from homozygous wtTP53 cells (Table 1, Figure 3) . Overall, 45% of the genomic transfections generated TROP1-expressing cells, with similar efficiency in the different groups. All transfectants were selected for amplification of the TROP1 gene (see below). Interestingly, amplified transfectants frequently presented with a broader, heterogeneous and unstable distribution of Trop-1 expression (Figure 3, d-f versus the remaining panels), confirming that an instability of the transfected TROP1 gene correlates with gene amplification (Alberti et al., 1994 ) (see below).
Gene copy number in the TROP1 transfectants
The TROP1 gene copy number of all transfectants was determined by Southern blotting. Significant gene amplification, that is from 4 to 10 gene copies per cell (Alberti et al., 1994) , was detected in 72% (18 of 25) of the TROP1 transfectants from three different strains of TP53-null Li-Fraumeni cells (Table 1 and Figure 4 ; see as examples tr 1 from mut/mut A; tr 2-4 from mut/mut B and tr 1 from mut/mut C). No amplification was observed when transfecting DNA from cells with homozygous wtTP53. Only a two-to threefold increase in gene copy number was observed in transfectants from TP53-heterozygous cells, possibly indicating a TP53 gene-dosage effect.
TROP1 is a single-copy gene in man (Calabrese et al., 2001) . Poisson distribution analysis of transfection p53 and DNA methylation AF Nasr et al frequencies indicated that most TROP1 transfectants originated from a single TROP1 gene transfection event per plate. Thus, each TROP1 transfectant is a rather homogeneous (in most cases clonal) population of Trop-1-expressing cells. This largely excludes that selection for TROP1 amplificants selects for cell subsets within a heterogeneous population. Growth rates and cloning efficiencies of cells expressing TROP1 at different levels were not significantly different (Alberti et al., 1994 and unpublished observations) . Thus, selection for TROP1 amplificants was not influenced by a differential cell growth or survival.
The TROP1 gene is not amplified in the TP53-null cells used as a source of DNA (Figure 4) , thus ruling out a cotransfection of multiple copies of the TROP1 gene in the recipient cells. Consistently, the gene was observed to amplify progressively during the selection procedure (Figure 4 ; confront the two successive cycles of selection of mut/mut B tr 2 and mut/mut C tr 1), confirming that gene amplification occurs after transfection in L cells.
To assess the reliability of the selection procedure for TROP1-amplified cells, the selection process was independently repeated on unselected transfectants, Figure 2 Scheme of the procedure used to detect TP53-related changes of DNA methylation. DNA from Li-Fraumeni cell strains or control cells was extracted and transfected in L cells. Transfected L cells were selected in HAT medium and Trop-1-expressing cells were selected by flow cytometry. Successive cycles of selection for the highest expressors revealed transfectants that had undergone gene amplification (Alberti et al., 1994) . p53 and DNA methylation AF Nasr et al frozen down before the selection procedure. A total of 10 transfectants from p53-null, 3 from heterozygous and 4 from homozygous wtTP53 cells were thawed 12 months later and selected for TROP1 amplification. The second selection procedure reproduced the same patterns of gene amplification (or lack of it) observed in the first one.
A longer selection (until the sixth round of flow cytometric selection) was tested on six transfectants from cells devoid of functional p53, on two from heterozygous wtTP53 cells and on two transfectants obtained using DNA methylated in vitro (see below). A higher final TROP1 gene copy number was observed in transfectants that progressively amplified the gene, (Alberti et al., 1994) . However, transfectants that did not amplify the TROP1 gene after two rounds of sorting could not be induced to do so by a longer selection for amplification.
Taken together, these findings strongly argue that the gene-amplification properties of each transfectant are deterministic and are reliably assessed by the selection procedure adopted in this work.
Methylation status of the TROP1 gene versus gene amplification
The methylation status of a transfected gene is largely retained over time in culture (Stein et al., 1982) . This was confirmed in our system (examples are the two successive cycles of selection of the wt/mut A tr 1 and 2 in Figure 5 ). As most genomic transfectants are clonal descendants of a single gene-transfection event, the methylation pattern of each TROP1 transfectant reveals information on the DNA methylation pattern of the original, single, transfected gene. This allowed to better see specific patterns of DNA demethylation 'singled out' from a heterogeneous population Li-Fraumeni cells. Notably, Southern blot analysis of TROP1 transfectants demonstrated a frequent loss of methylation at specific sites of the amplified TROP1 genes. In some instances a complete demethylation of specific CpG sites was revealed ( Figure 5, arrowhead) .
To confirm that the amplification of TROP1 was due to a lower level of methylation of the gene, DNA from TP53-null cell lines (mut/mut B and C) was extensively methylated at CpG sites in vitro using the SssI DNA methylase (Figure 6 ). L cells were tansfected with the methylated DNA, and TROP1 transfectants were selected for gene amplification. The expression of the TROP1 gene is not affected by its DNA methylation status (Alberti et al., 1994) , thus allowing efficient selection of transfectants irrespective of their methylation levels. Consistently, using in vitro methylated DNA TROP1 transfectants were obtained at the same high frequency as with untreated DNA. However, no gene amplification was observed (Figure 7 , Table 1 ). In other words, the in vitro methylation annihilated the amplification ability of TROP1 genes from Li-Fraumeni cells. This demonstrated that the demethylation of TROP1 genes from TP53-null cells is critical to gene amplification.
TP53 dependence of the demethylation and amplification of the TROP1 gene
To confirm that the loss of TP53, rather than additional genetic or epigenetic changes accumulated by LiFraumeni cells in culture, causes DNA demethylation, mut/mut B and mut/mut C cells were transfected with a wtTP53 (Blandino et al., 1995) . Successful transfection was confirmed by Southern blotting. Transfected cells stopped dividing within 2 weeks from the transfection, confirming functional responsiveness to the reintroduction of a wt p53 (Yin et al., 1992) . DNA was extracted from TP53-transfected Li-Fraumeni cells and assayed for gene amplification in L cells. Remarkably, the TROP1 genes from mut/mut C cells expressing a wtTP53 did not amplify (Figure 8 , Table 1 ), demonstrating that the transfection of a wtTP53 reverts the amplification-prone status of the TROP1 gene, and confirming the causal relation between the presence of a functional TP53 and the maintenance of DNA Figure 5 Methylation levels of the TROP1 gene in transfectants. DNA samples were digested with BamHI and with HpaII or MspI. Representative transfectants at successive cycles of selection are shown; 1st: first sort; 2nd: second and final sort. Marked hypomethylation of the amplified DNA was observed in tr 2 and tr 3 from mut/mut B DNA (arrowhead). PBL: human peripheral blood leukocytes; L: untransfected L cells. Arrows: l HindIII m.w. markers. The filter was hybridized with a human TROP1 probe p53 and DNA methylation AF Nasr et al methylation levels. The differential response of mut/mut C versus mut/mut B suggests that further genetic/ epigenetic changes can occur in the TP53-null cells and may not be fully reverted by the reintroduction of a wtTP53. This is consistent with the observation that the reintroduction of TP53 in TP53-null cells reverts only in part the DNA methylation levels of the TROP1 gene.
Discussion
DNA methylation plays a central role in the maintenance of chromatin structure and genome integrity (Hori, 1983; Xu et al., 1999; Tuck-Muller et al., 2000) and is causally linked to gene amplification (Perry et al., 1992; Alberti et al., 1994) . In an intriguing parallel, p53 plays an analogous control role over genome stability, homologous recombination and gene amplification (Livingstone et al., 1992; Yin et al., 1992; Bertrand et al., 1997; Carroll et al., 1999; Saintigny and Lopez, 2002) . Thus, we argued that p53 might act upstream of the DNA methylation apparatus and regulate its activity. A potential link between p53 and DNA methylation was of high potential interest, as widespread changes in DNA methylation are observed in several tumor types where p53 inactivation is frequent (Laird and Jaenisch, 1994) and gross genome instability and gene amplification are caused by the inactivation of p53 (Livingstone et al., 1992; Yin et al., 1992; Soares et al., 1999) .
Li-Fraumeni syndrome cells carry a germline mutation of TP53 (Malkin et al., 1990) and lose or inactivate the remaining copy of TP53 over time in culture (Livingstone et al., 1992; Yin et al., 1992) . Preliminary findings demonstrated overall DNA hypomethylation in TP53-null cells by digesting genomic DNA with the methyl-C-specific McrBC nuclease (Pradhan and Kim, 2002) . As the TROP1 gene undergoes gene amplification in a DNA methylation-dependent manner (Alberti et al., 1994) , it was analysed for DNA methylation changes in TP53-null cells. Profound demethylation of the TROP1 gene was revealed by Southern blotting. Little information is available on the DNA regions that are important for the methylation-mediated control of the structural integrity of DNA (Wahl et al., 1984; Alberti et al., 1994; Coquelle et al., 1997; Jones and Gonzalgo, 1997) . Thus, the relevance of the methylation changes in the TROP1 gene in Li-Fraumeni cells was tested after transfection in L cells, that is, a permissive environment for gene amplification (Alberti et al., 1994) . We detected significant gene amplification, that is 4-10 fold increase in gene copy number (Alberti et al., 1994) , in a large fraction of the TROP1 transfectants from three different strains of TP53-null Li-Fraumeni cells. No amplification was observed when transfecting DNA from cells with homozygous wtTP53. Only a marginal increase in gene copy number was observed in transfectants from TP53-heterozygous cells, indicating a possible TP53 gene-dosage effect. Southern blot analysis demonstrated marked hypomethylation of the amplified TROP1 genes, whereas in vitro DNA methylation abolished the amplification of TROP1, thus demonstrating that the demethylation of the TROP1 gene in TP53-null cells is critical to gene amplification.
To confirm that the loss of TP53, rather than additional genetic or epigenetic changes in Li-Fraumeni cells, causes DNA demethylation, the mut/mut B and mut/mut C cells were transfected with a wtTP53 (Blandino et al., 1995) . Remarkably, the TROP1 gene regained methylation at CpG sites and did not amplify, indicating that the transfection of wtTP53 reverts the amplification-prone status of the TROP1 gene. These findings establish a casual relation between the TP53 activity and the maintenance of DNA methylation levels. The heterogeneous response of TP53-null cells to the reintroduction of wtTP53 suggests that further genetic changes can occur in these cells after the loss of p53, which may not be reverted by the wtTP53. Taken together, our findings demonstrate that the inactivation of p53 causes loss of DNA methylation and subsequent gene amplification.
It will be of interest to determine if TP53-dependent changes in DNA methylation of loci other that TROP1 occur and if they will be similarly linked to genetic instability. The overall hypomethylation that is frequently observed in cancer cells (Soares et al., 1999) is consistent with this model. However, regions of local hypermethylation (Makos et al., 1992; Esteller et al., 2001) are commonly observed in the same transformed cells, indicating that changes in DNA methylation are not evenly distributed over the genome. Different DNA methyltransferases play diverse roles and are differentially regulated . Hence, it will be crucial to dissect their regulatory pathways, overall function and gene specificity in TP53-null cells.
p53 may influence the DNA methylation apparatus through short-range interactions, as both p53 and DNA methylases reside in complexes with histone acetylases or deacetylases (Murphy et al., 1999; Blobel, 2000; Fuks et al., 2001) . Alternatively, this may occur through p53-dependent gene-expression regulatory loops (Murphy et al., 1999) . Finally, longer-range functional interactions could be mediated by the role of p53 on the control of cell growth or induction of apoptosis (Levine, 1997) . Further work is required to clarify which of these pathways plays the major role in the control of the DNA methylation apparatus.
These findings raise the possibility of a relation between DNA methylation and functions of p53 other than the control over genome stability. Consistently, a functional link has been demonstrated between DNA methylation and TP53-mediated apoptosis (JacksonGrusby et al., 2001) , as loss of DNA methylation in fibroblasts from knockout mice for the Dnmt1 gene specifically triggers the proapoptotic activity of Recent findings have demonstrated that the ablation of retinoblastoma gene (RB) induces genomic instability (Zheng et al., 2002) . The Rb protein directly interacts with the Dnmt 1 and DNA methyltransferase regulates its function (Pradhan and Kim, 2002) . This intriguingly parallels the role of p53 in the control of genome stability and the interaction between p53 and the DNA methylation apparatus indicated by our findings. Thus, key interactions occur between major safeguard systems for genomic integrity (TP53, RB and DNA methylation). As a consequence, genome instability, rather than being a stochastic consequence of tumor progression, is suggested to be a direct consequence of alterations of TP53 and RB, possibly mediated by a derangement of DNA methylation. Conversely, the frequency and specific appearance of genome rearrangements during tumor progression in man (Rabbitts, 1994; Jones and Gonzalgo, 1997; Mitelman, 2000) raise the possibility that this 'common pathway' leading to genomic rearrangements may mediate key steps of the tumorigenic conversion caused by the inactivation of TP53 and RB.
